Table 2.
Clinical, laboratory, and angiographic data of the patients with and without contrast-induced nephropathy.
| Variables | Group 1 CIN (n = 41) | Group 2 No CIN (n = 259) | P-Value |
|---|---|---|---|
| Age (years) | 55.68 ± 8.31 | 54.93 ± 9.74 | 0.64 |
| Female | 10 (24.3%) | 75 (28.9%) | 0.54 |
| Smoking/tobacco use | 29 (70.7%) | 169 (65.3%) | 0.49 |
| Hypertension | 28 (68.3%) | 92 (35.5%) | 0.0001 |
| Diabetes mellitus | 29 (70.7%) | 33 (12.7%) | 0.0001 |
| Previous CAD | 10 (24.4%) | 29 (11.2%) | 0.02 |
| Previous CABG | 2 (4.9%) | 3 (1.2%) | 0.08 |
| Previous CVA | 5 (12.2%) | 4 (1.5%) | 0.0001 |
| Pre-existing renal disease | 4 (9.8%) | 6 (2.3%) | 0.01 |
| Peripheral vascular disease | 3 (7.3%) | 16 (6.2%) | 0.78 |
| LVEF (%) | 40.29 ± 9.15 | 47.63 ± 8.81 | 0.0001 |
| Killip class ≥2 | 29 (70.7%) | 25 (9.6%) | 0.0001 |
| Weight (kg) | 76.59 ± 10.63 | 76.47 ± 9.56 | 0.94 |
| Body mass index (kg/m2) | 23.24 ± 2.20 | 23.10 ± 1.97 | 0.68 |
| Total cholesterol (mg/dL) | 213.39 ± 32.64 | 202.51 ± 29.98 | 0.034 |
| HDL (mg/dL) | 41.22 ± 4.13 | 42.56 ± 14.16 | 0.55 |
| LDL (mg/dL) | 141.90 ± 27.33 | 132.04 ± 29.07 | 0.04 |
| Triglyceride (mg/dL) | 151.93 ± 46.36 | 138.27 ± 30.15 | 0.01 |
| Systolic blood pressure (mm of Hg) | 148.39 ± 34.75 | 134.32 ± 24.29 | 0.001 |
| Diastolic blood pressure (mm of Hg) | 89.37 ± 15.12 | 85.08 ± 50.12 | 0.59 |
| Hemoglobin (g/dL) | 11.74 ± 1.35 | 12.97 ± 1.38 | 0.0001 |
| Serum creatinine (mg/dL) | 1.07 ± 0.35 | 0.99 ± 0.28 | 0.12 |
| eGFR (mL/min) | 83.76 ± 19.22 | 90.61 ± 20.75 | 0.04 |
| 48 h peak serum creatinine (mg/dL) | 1.96 ± 0.33 | 1.07 ± 0.30 | 0.0001 |
| 7th day serum creatinine (mg/dL) | 1.34 ± 0.46 | 1.01 ± 0.28 | 0.0001 |
| Contrast volume (mL) | 204.39 ± 52.49 | 136.03 ± 43.81 | 0.0001 |
| Iodixanol use | 5 (31.2%) | 11 (68.8%) | 0.04 |
| No. of vessels | 1.98 ± 0.79 | 1.55 ± 0.67 | 0.0001 |
| No. of stents | 2.24 ± 0.83 | 1.62 ± 0.70 | 0.0001 |
| CHA2DS2-VASc score | 4.15 ± 1.35 | 2.25 ± 0.92 | 0.0001 |
| ACE inhibitor/ARB use | 29 (70.7%) | 139 (53.7%) | 0.04 |
| Previous metformin use | 19 (46.3%) | 18 (6.9%) | 0.0001 |
ACE; angiotensin converting enzyme; ARB; angiotensin receptor blocker; CAD, coronary artery disease; CVA, cerebrovascular accidents; CABG, coronary artery bypass graft; CIN, contrast-induced nephropathy; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction.